Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
Open Access
- 23 July 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Allergy, Asthma & Clinical Immunology
- Vol. 17 (1), 1-7
- https://doi.org/10.1186/s13223-021-00579-6
Abstract
Hereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks. To describe our clinical findings from a case series of adult patients with HAE type 1/2 who have been initiated on lanadelumab. A chart review of HAE type 1/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted. Patients were included if they had been receiving lanadelumab for at least 6 months. Patients with other causes of angioedema were excluded. 12 patients meeting enrollment criteria were identified. Compared to pre-lanadelumab, patients had mean reductions of 72% and 62% in attack rate and treated attack rate respectively. 3 patients reported complete remission from attacks after starting lanadelumab. Most patients had significant improvements in HAE impact on social outings. Our case series findings support the 2019 International/Canadian HAE guideline that lanadelumab is an effective therapy for long term prophylaxis. In our patient population, initiation of lanadelumab improved disease control, minimized the burden of treatment and improved HAE impact on social outings.Keywords
This publication has 18 references indexed in Scilit:
- Melkersson–Rosenthal syndrome: a case report of a rare disease with overlapping featuresAllergy, Asthma & Clinical Immunology, 2019
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema AttacksJAMA, 2018
- SUBCUTANEOUS SELF-ADMINISTRATION OF LANADELUMAB FOR PROPHYLACTIC TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE)Annals of Allergy, Asthma & Immunology, 2018
- Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorThe New England Journal of Medicine, 2017
- Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisThe New England Journal of Medicine, 2017
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary AngioedemaThe New England Journal of Medicine, 2010
- Summary and Conclusions: New Perspectives in Hereditary Angioedema: Molecular Mechanisms and Therapeutic Choices: A CME Symposium Presented at the World Allergy Congress, Buenos Aires, Argentina (December 2009)World Allergy Organization Journal, 2010
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006
- Plasma bradykinin in angio-oedemaThe Lancet, 1998